Neural-hematopoietic-inflammatory axis in nonsmokers, electronic cigarette users, and tobacco smokers.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Ruedisueli (2022)
Pharmacokinetic and pharmacodynamic properties of aerosolized (“vaped”) ThC in adolescent male and female rats.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Ruiz (2021)
Pod-mod vs. conventional e-cigarettes: nicotine chemistry, ph, and health effects.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Shao (2020)
are E-Cigarette Flavors associated with Exposure to Nicotine and Toxicants? Findings from Wave 2 of the Population assessment of Tobacco and health (PaTh) Study.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Smith (2019)
Differences in Exposure to Nicotine, Tobacco-Specific Nitrosamines, and Volatile Organic Compounds among Electronic Cigarette Users, Tobacco Smokers, and Dual Users from Three Countries.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Smith (2020)
Nicotine absorption from e-cigarettes over 12 months.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Soar (2019)
Rapid Brain Nicotine Uptake from Electronic Cigarettes.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Solingapuram (2020)
hydroxyl Radicals in E-Cigarette Vapor and E-Vapor Oxidative Potentials under Different Vaping Patterns.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Son (2019)
Investigating E-Cigarette Particle Emissions and human airway Depositions under Various E-Cigarette-Use Conditions.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Son (2020)
Thermodynamic behaviour of an e-cigarette: Investigation of nicotine delivery consistency using nicotine yield.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
Soulet (2022)